AstraZeneca has finalized an exclusive global license agreement for CMG901, signaling a strategic move to enhance its product portfolio. Despite a recent decline in shares and regulatory hurdles, the company reported a net income of $3.08 billion for the latest quarter, reflecting a 21.7% EPS growth quarter-over-quarter. Analysts remain optimistic, issuing a 'Buy' rating and projecting a target price increase of over 20%, underpinned by strong fundamentals and ongoing investments in R&D.
“AstraZeneca · completed · license agreement · exclusive global agreement for CMG901”
“AstraZeneca PLC · P/E Ratio · P/E Ratio · 27.57”
“AstraZeneca PLC · Price/Book · Price/Book · 5.95”
“AstraZeneca PLC · Debt / Equity · Debt / Equity · 71.82%”
“AstraZeneca PLC · Return on Equity · Return on Equity · 23.48%”
“AstraZeneca PLC · Dividend Yield · Dividend Yield · 1.73%”
“AstraZeneca PLC · EBITDA · EBITDA · 19.28B”
“AstraZeneca PLC · Total Revenues · Total Revenues · 58,739”
“AstraZeneca PLC · Gross Profit · Gross Profit · 47,993”
“AstraZeneca PLC · Operating Income · Operating Income · 14,292”
“AstraZeneca PLC · Net Income · Net Income · 10,225”
“AstraZeneca PLC · Total Assets · Total Assets · 114,074”
